A Research Study of OBI-902 in Participants with Advanced Solid Tumors.

Trial ID:
IRB-25-8639
Darren Sigal, M.D.

Inclusion Criteria

Patients must:

  • have metastatic or advanced solid tumor that is not curable with local therapies.
    have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently effective.
    be willing and able to comply with all protocol-required assessments, visits, and procedures, including pretreatment tumor biopsy.
    must have a negative pregnancy test (female patients) and agree to use a reliable form of contraceptive during the study treatment period and for at least 7 months following the last dose of study drug.
    not be breastfeeding.

Exclusion Criteria

Patients must not:

  • have chemotherapy or radiation therapy within 3 weeks of the start date of the study drug.
    have a surgical procedure within 28 days of the start of the study drug.
    have had an organ transplant. Corneal transplant without immunosuppressive therapy is allowed.

Additional Info

Further blood tests, cardiology assessments, and review of prior medical history will be completed to determine full eligibility.

All treatment and physician visits during this study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion) and Scripps Green Hospital.

For additional information, search NCT#07124117 on the ClinicalTrials.gov website (https://clinicaltrials.gov)

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org